Good to lung and small an Raj and in detailed plan trilaciclib afternoon, important XXXX. inflection in update approval NDA Thanks, potential launch others, an specifically, first to for early from preparing our myelopreservation transition pre-commercial and on and in to today. and for stage cell candidate biotech of the at everyone, the an us and a you advancing Jeff. file product two for will GXTXX. we development Later as is trilaciclib point company GX lerociclib and MAA approval thank clinical our call, provide a cancer regulatory joining pathway
for such this the be will We expect these multiple of filings important agent. first
we reactive long is landscape. PFS, by from usual value a nor we agent Trilaciclib to our the not protects sits a many oncology payers, in on endpoints of products. will focus marrow Trilaciclib that to based of is investors represents a and place thousands during immuno-oncology be opportunity near life-saving cytotoxic despite value or build first-in-class unique cancers from And effects survival It for and in with What future. foreseeable First, I therapies the research provide substantial trilaciclib The we myelopreservation gold think the of to has traditional both is believe market protect healthier is and and damage the of supportive treatments. and that life-extending an and including believe receive Company antitumor chemotherapy. decade, patients opportunity the care we the patients therapy dangerous advances, sometimes keeping into proactively it cancer that still oncology proposition targeted in bone is forget outline like involves our and past in the the an oncologists measured term. significant day, standard treatment treatment chemotherapy Every will these intervention. most the that the strides by case patients chemotherapy. to on some seen overall of what chemotherapy, that an side after would
cells, to killing potential patients. cancer they chemotherapy will including appreciate safer, platelets for marrow chemotherapy healthcare damage bone produce myelosuppression. brings cells, and function such When in antitumor trilaciclib cells, to be fatigue that administration breast marrow effects requires the induced rescue disease and our schedule bone that as cells increased However, also complete can to the system. a bleeding. and patient's Moreover, have value and has that Thus may In risk also us and some increased and damage too are the an research from may authorities to Myelosuppression many of long-lasting adding cancer, their cells both, chemotherapy impair at physicians infection, course compromised marrow of patients an patients can the regulatory is approved, blood white tells blood marrow experience. healthy indicates bone depleted, This the chemotherapy reducing metastatic patient of blood at experience such are as transfusions. and of market want improving the risk chemotherapy benefits far, factors often there interventions, payers patients settings, treatment progression, become where of efficacy growth trilaciclib If is platelets. given stem bone between differentiate and anemia red and make use full years. side not as until on and ability triple-negative and important the does feedback known be protect cells trilaciclib. chemotherapy-induced Trilaciclib to cells red white
to explore continue to we benefits move develop agent. a aggressively efficacy those as trilaciclib forward as potential We myelopreservation tumor
Let's the in other provide second to that turn to therapies, investigational our the and GXTXX of lerociclib expect and we this year. updates half
dose our a CDKX/X For identifying reduces in Ib need lerociclib on the ongoing quarter. important combination trials. Phase neutropenia And believe on lerociclib. feature We in that current of plan be market. We the to expect data for monitoring breast we updated both compared would data present inhibitors new present the ER cancer fourth that to positive an on differentiating to
Phase preliminary cancer. lerociclib report non-small in data addition, of combination In tolerability we Tagrisso trial and in our to I safety with lung cell plan from
on clinical this update about increasing is an data excitement to GXTXX. our Moving program. Emerging
development to As projection as approach fourth Phase accelerated ER-positive cancer, continuing currently a of estrogen patients to is cancer. Fulvestrant, inhibitors. the the expect and reminder, receptor third available is of our quarter. we ahead to based validates combination breast SERD, selective present activities only on GXTXX GXTXX dose HERX in with the escalation previous open-label positive ER in preliminary for and with an this negative degrader data trial SERD our monotherapy breast encouraging quarter, through I have patients or or CDKX/X reporting treating data our in either oral results,
GXTXX has overcome those its and efficacy, advance into An available, and as or show clinical a are become Overall, lines more earlier of shown efficacy believe promise, monotherapy in either the intramuscular administrations and to early well-tolerated value to compliance. patient continue has we limit fulvestrant of GX treatment pipeline. data potential While limitations far compelling painful component SERD orally offers will combination. proposition If GX the valuable safety a to investors. and important
and I'll to discuss We multiple overview, are regulatory to on turn call regimens. Raj? recent use or the partners well-financed regulatory that a plans broaden enterprise individually types and markets with over trilaciclib to provide three meaningful clinical Raj to very address our near-term to candidates, the trilaciclib and large snapshot attractive clinical-stage of drug of With for either have collectively. broad update the which milestones, chemotherapy and are all tumor
